Join our newsletter

Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM

APILAM informs you that the personal data that you provide to us by filling in this form will be treated by APILAM as responsible for this web. The purpose of the collection and processing of personal data that we request is to manage the registration of this subscription and send periodic bulletins with information and prospective offer of products or services.

Legitimation: Consent of the interested party

As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).

The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.

You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.

You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.

Last update Oct. 11, 2017

Triamcinolone (topical use)

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

A corticosteroid with a mainly glucocorticoid action and moderate anti-inflammatory effects (ATC D07AB), slightly higher than that of prednisolone (ATC D07AA).
Its topical dermatological use is indicated in the treatment of various types of dermatitis.

This comment is about the TOPICAL USE of triamcinolone.

Limited absorption through the skin and even mucous (Ramadas 2016, Meynadier 1981, Rasmussen 1978) makes it unlikely that significant amounts will pass into breast milk.

If it is required to treat eczema or dermatoses of the nipple, it is advisable to choose the mildest corticoid, apply it just after the feed is finished so that it has been reabsorbed before the next feed, if it is necessary residues can be removed with a gauze and do not use it for more than a week after.

Mineralocorticoid intoxication has occurred in an infant due to continuous application of a corticoid to the nipple (De Stefano 1983).

It is advisable to avoid application to the nipple of creams, gels and other topically-applied products that contain paraffin (mineral oil) so that the infant does not absorb them (Concin 2008, Noti 2003).

See below the information of these related products:

Triamcinolone Inhaled ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
Triamcinolone Sistemic Use (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

Hydrocortisone, Topical Use (dermatological, ophthalmic, otic, intestinal enema) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Very Low Risk

High Risk

Very High Risk

Very Low Risk

High Risk

Very High Risk

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Triamcinolone (topical use) belongs to this group or family:

ATC D07A: Corticoid, dermatological, topical use

Tradenames

Main tradenames from several countries containing Triamcinolone (topical use) in its composition:

Aldoderma™. Contains other elements than Triamcinolone (topical use) in its composition
Anso™. Contains other elements than Triamcinolone (topical use) in its composition
Positon™. Contains other elements than Triamcinolone (topical use) in its composition

Pharmacokinetics

Variable	Value	Unit
Oral Bioavail.	Baja - Poor (dermat)	%
Molecular weight	394	daltons
Protein Binding	68	%
VD	1.4	l/Kg
pKa	13.4	-
T½	2	hours

References

List of 6 references

Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 0.1% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016 Abstract
Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract
Meynadier J, Guilhou JJ, Peyron JL. [Percutaneous absorption of triamcinolone 16 alpha, 17 alpha cyclopentylene-dioxy-21-acetate (author's transl)]. Dermatologica. 1981 Abstract
Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol. 1978 Abstract

Total visits

22,889

Triamcinolone (topical use)

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Alternatives

Other names

Group

Tradenames

Pharmacokinetics

References

Total visits

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?